Surmodics (SRDX) Stock Price
Surmodics Price
Over the last 19 years Surmodics grew revenue by 3.8% annually, reaching 126.08 M USD. Earnings per share have declined at 8.2% per year over the last 15 years. For Surmodics, the net margin of -9.2% is down versus 1.2% a few years ago. The consensus 12-month price target for Surmodics is 43.86 USD, about 2.0% above where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Surmodics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Surmodics business model & stock analysis
Frequently asked questions about Surmodics
Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.
Surmodics Inc is primarily active in the healthcare and medical device industry.
The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.
Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.
Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.
Surmodics Inc is primarily present in the United States.
Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.
Analysts currently set an average price target of 43.86 USD for the Surmodics stock (median: 43.86 USD), implying +2.0 % versus the latest price. The consensus is based on 9 analyst ratings.
7 analysts currently rate the Surmodics stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Surmodics to generate revenue of 123.01 M USD and earnings per share of -0.12 USD.
Converted at the current exchange rate, the Surmodics share trades at 38.36 EUR (42.98 USD).
The Surmodics share (SRDX) is listed on 2 stock exchanges, including: NASDAQ (SRDX), Frankfurt (SU6.F).
Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.
The expected revenue of Surmodics is 123.01 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Surmodics is -1.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Surmodics is currently -356.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Surmodics stock.
The price-to-sales ratio (P/S) of Surmodics is currently 4.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Surmodics stock.
The Eulerpool Quality Score for Surmodics is 2/10.
The ISIN of Surmodics is US8688731004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Surmodics is 914178. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Surmodics is SRDX. The ticker symbol is used to trade Surmodics shares on the stock exchange.
Surmodics stock
Surmodics Peer Group
Surmodics Ticker
Surmodics FIGI
All fundamentals and in-depth analysis of Surmodics
Our stock analysis for Surmodics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surmodics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.